Q-omics provides the consensus-scored FGF20 profile across patient tissues and cancer cell-line models. FGF20 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FGF20 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FGF20 RNA expression shows 16,336 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where FGF20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGF20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGF20 survival associations across molecular data types. FGF20 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGF20 RNA expression–survival associations across cancer types. High FGF20 expression shows unfavorable associations in LGG and UVM, but favorable associations in UCEC, KIRP, MESO and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for FGF20 RNA expression.
This table summarizes FGF20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FGF20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGF20 shows lower tumor expression in HNSC and BRCA and higher tumor expression in KIRC, COAD, THCA and READ. The KIRC box plot shows higher FGF20 RNA expression in tumor versus normal tissue (log2 FC = +0.317, t-test p < 0.001).
This table shows molecular features associated with FGF20 in patient tissues and cancer cell lines. In patient samples, FGF20 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FGF20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and CNS.
